Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Add as a preferred source on Google
SAN DIEGO, Feb. 21, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 73756754 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
